UTHR · XBRL financial data

United Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (UTHR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	1,483	—	—	—	—	—
Revenue from contracts with customers	1,483	1,686	1,936	2,328	2,877	3,183
Cost of goods and services sold	108	123	152	258	310	384
Gross profit	1,375	1,563	1,785	2,070	2,568	2,798
Research and development	358	540	323	408	481	550
Selling, general and administrative	—	467	482	477	710	756
Operating income (loss)	594	556	980	1,185	1,377	1,493
Interest income	29	17	45	163	199	192
Interest expense	24	19	32	59	43	20
Other income (expense)	49	42	(40)	(14)	6	49
Income tax expense (benefit)	124	118	223	290	344	379
Net income (loss)	—	476	727	985	1,195	1,335
Earnings per share, basic USD per share	11.65	10.60	15.98	21.04	26.44	30.13
Earnings per share, diluted USD per share	11.54	10.06	15.00	19.81	24.64	27.86
Weighted average shares, basic millions of shares	44	45	46	47	45	44
Weighted average shares, diluted millions of shares	45	47	49	50	49	48

Fiscal years (UTHR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	739	895	961	1,208	1,697	1,557
Marketable securities	1,096	1,036	1,878	1,786	1,570	1,363
Marketable securities, non-current	1,150	1,650	1,316	1,910	1,475	1,777
Accounts receivable	157	199	220	279	279	350
Inventory	87	94	102	112	158	183
Total current assets	2,167	2,324	3,380	3,551	3,874	3,703
Property and equipment, net	732	781	862	1,045	1,222	1,730
Goodwill	28	28	28	34	32	32
Total assets	4,615	5,169	6,045	7,167	7,364	7,880
Accounts payable	4	4	4	6	6	7
Accrued liabilities	183	171	226	292	339	481
Total current liabilities	323	305	343	804	738	561
Total liabilities	1,220	1,210	1,248	1,182	920	784
Retained earnings	3,839	4,315	5,042	6,027	7,222	8,557
Total stockholders' equity	3,395	3,959	4,797	5,985	6,444	7,096
Total liabilities and equity	4,615	5,169	6,045	7,167	7,364	7,880
Common shares outstanding (cover page) millions of shares	45	45	46	47	45	44

Fiscal years (UTHR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	476	727	985	1,195	1,335
Stock-based compensation	164	139	107	39	144	148
Depreciation and amortization	50	50	51	53	73	86
Net cash from operating activities	756	598	803	978	1,327	1,561
Purchases of property and equipment	59	121	139	230	247	521
Net cash from investing activities	(739)	(487)	(812)	(720)	417	(551)
Share repurchases	—	—	0	0	1,000	1,000
Net cash from financing activities	(17)	45	75	(12)	(1,255)	(1,150)
Net change in cash	0	156	66	247	490	(140)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
United Therapeutics	1,189	833	not reported	42.6M	—	Q3 FY26 10-QSep 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
BeOne Medicines	5,098	1,705	463*	1.5B	—	Q2 FY26 10-QJun 30, 2026
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	—	Q3 FY26 10-QSep 30, 2026
Biogen	1,304	2,804	641*	147.8M	—	Q3 FY26 10-QSep 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.